An update from Karolinska Development AB ( ($SE:KDEV) ) is now available. Karolinska Development’s portfolio company, Modus Therapeutics, has ...

STOCKHOLM, SWEDEN November 4, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics, has received regulatory approval to initiate the ...

The global population is ageing and this demographic shift has profound effects on haemostasis, notably a progressive tilt ...

Drinking green tea is safe for most people but consuming large amounts may raise the risk of iron deficiency anemia, liver problems, and drug interactions ...

Skin conditions, diet choices, and some chronic health conditions may make the bottom of your feet yellow. Treating the cause ...

A 56-year-old man was admitted to the hospital because of left lower abdominal pain and anemia. He had a 1-year history of ...

Akebia shares decline after the company ends plans for its VALOR trial, citing FDA feedback and high costs tied to expanding ...

The decision came following a meeting with the FDA during which the Company and the Agency could not come to an agreement on the design of the VALOR clinical trial.

Akebia Therapeutics has scrapped plans for trial that would have potentially led to an expansion of the patient population for its new anemia drug Vafseo, the company said.

Shares of Akebia Therapeutics fell sharply premarket after it abandoned plans for a clinical trial of its anemia treatment in patients not on kidney dialysis following a meeting with the Food and Drug ...

aInstitute of Nephrology, Madras Medical College, Member-Secretary, Transplant Authority of Tamil Nadu (TRANSTAN), India bInstitute of Community Medicine, Madras Medical College, India cInstitute of ...